---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-004481"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-06-03T13:00:15+00:00"
generated_at: "2026-06-03T13:02:29.138408+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Valion Bio shareholders approve 2.58M share increase to 2021 equity plan; Dean Zikria re-elected

## Summary
- Shareholders approved a 2,581,608 share increase under the 2021 Equity Incentive Plan (736,919 for, 134,918 against).
- Dean Zikria was elected Class II director with 873,001 votes for and 59,543 withheld.
- Ratification of Rosenberg Rich Baker Berman as auditor for FY 2026 passed with 1,510,322 votes for.
- Proposals 4-7 (issuances to institutional investors and Tumim) approved with ~65-66% of votes cast in favor.
- Adjournment proposal approved (1,328,670 for) but not needed as all other proposals passed.

## SEC filing metadata
- accession: 0001683168-26-004481
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-06-03T13:00:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-004481
- JSON: https://secwatch.observer/filing/0001683168-26-004481.json
- Plain text: https://secwatch.observer/filing/0001683168-26-004481.txt

## Key facts
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock and exercise of related warrants to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
  - Outcome: passed
  - Meeting: 2026-05-28
  source text: Votes For Votes Against Abstentions Broker Non-Votes 333,682 152,377 135,011* 637,190
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series C Preferred Stock and exercise of related warrants (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
  - Outcome: passed
  - Meeting: 2026-05-28
  source text: Votes For Votes Against Abstentions Broker Non-Votes 332,353 153,606 135,111* 637,190
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Approval of sale and issuance of common stock pursuant to Common Stock Purchase Agreement with Tumim Stone Capital, LLC (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
  - Outcome: passed
  - Meeting: 2026-05-28
  source text: Votes For Votes Against Abstentions Broker Non-Votes 333,345 153,008
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Approval of Plan Amendment to increase shares authorized under the 2021 Amended and Restated 2021 Equity Incentive Plan by 2,581,608 shares at the 2026-05-28 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-05-28
  source text: Votes For Votes Against Abstentions Broker Non-Votes 736,919 134,918 60,707 637,190
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Senior Secured Convertible Note and exercise of warrant to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
  - Outcome: passed
  - Meeting: 2026-05-28
  source text: Votes For Votes Against Abstentions Broker Non-Votes 332,456 153,503 135,111* 637,190
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Ratification of Rosenberg Rich Baker Berman, P.A. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-05-28
  source text: Proposal No. 3: The Company’s stockholders ratified the selection of Rosenberg Rich Baker Berman, P.A.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Election of one Class II director at the 2026-05-28 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-05-28
  source text: Name of Director Votes For Withhold Broker Non-Votes Dean Zikria 873,001 59,543 637,190
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/0001683168-26-004481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.